Literature DB >> 1914227

Urinary IL-6: a marker for mesangial proliferative glomerulonephritis?

C Gordon1, N Richards, A J Howie, K Richardson, J Michael, D Adu, P Emery.   

Abstract

A prospective study of plasma and urinary interleukin-6 (IL-6) levels was performed in 54 patients undergoing renal biopsy to determine whether detectable urinary IL-6 was a reliable marker for mesangial proliferation. Interleukin-6 was found in both the urine and plasma of seven patients, the urine alone of 15 patients, and the plasma alone of two patients. Interleukin-6 was not detected in the urine or the plasma of the remaining 30 patients, the urine of 10 healthy controls or the urine of 10 patients with rheumatoid arthritis with raised plasma IL-6. Interleukin-6 was found in the urine of only one out of an additional seven patients with lupus nephritis. Urinary IL-6 was associated with a variety of renal abnormalities and was not restricted to those with mesangial hypercellularity. Furthermore, many patients with mesangial hypercellularity did not have detectable urinary IL-6. There was no correlation between urinary IL-6 and plasma IL-6, urinary albumin excretion or urinary creatinine. These results suggest that IL-6 detected in the urine is a marker of renal IL-6 production, but not specifically of mesangial hypercellularity. The patients with IL-6 in the urine had a mean serum creatinine significantly higher than those without IL-6. It is not possible to distinguish at present whether IL-6 contributes to renal dysfunction or whether it reflects renal damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914227      PMCID: PMC1554150          DOI: 10.1111/j.1365-2249.1991.tb05787.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response.

Authors:  J M Le; J Vilcek
Journal:  Lab Invest       Date:  1989-12       Impact factor: 5.662

2.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors:  B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

3.  The prognostic significance of urinary interleukin 6 in IgA nephropathy.

Authors:  K Dohi; M Iwano; A Muraguchi; Y Horii; T Hirayama; S Ogawa; H Shiiki; T Hirano; T Kishimoto; H Ishikawa
Journal:  Clin Nephrol       Date:  1991-01       Impact factor: 0.975

4.  Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  B Dasgupta; G S Panayi
Journal:  Br J Rheumatol       Date:  1990-12

5.  Functional discrimination between interleukin 6 and interleukin 1.

Authors:  M Helle; L Boeije; L A Aarden
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

6.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.

Authors:  F A Houssiau; J P Devogelaer; J Van Damme; C N de Deuxchaisnes; J Van Snick
Journal:  Arthritis Rheum       Date:  1988-06

7.  Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis.

Authors:  J M Boswell; M A Yui; D W Burt; V E Kelley
Journal:  J Immunol       Date:  1988-11-01       Impact factor: 5.422

8.  Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.

Authors:  M H Van Oers; A A Van der Heyden; L A Aarden
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

9.  Novel and enhanced IL-1 gene expression in autoimmune mice with lupus.

Authors:  J M Boswell; M A Yui; S Endres; D W Burt; V E Kelley
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

10.  IgG1 plasmacytosis in interleukin 6 transgenic mice.

Authors:  S Suematsu; T Matsuda; K Aozasa; S Akira; N Nakano; S Ohno; J Miyazaki; K Yamamura; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  10 in total

Review 1.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

Review 2.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

Review 3.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

5.  Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis, and a potential target of immunoglobulin therapy?

Authors:  G Rostoker; J C Rymer; G Bagnard; M Petit-Phar; M Griuncelli; Y Pilatte
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

6.  Genetic susceptibility to idiopathic membranous nephropathy in high-prevalence Area, Taiwan.

Authors:  Shih-Yin Chen; Cheng-Hsu Chen; Yu-Chuen Huang; Chia-Jung Chan; Da-Chung Chen; Fuu-Jen Tsai
Journal:  Biomedicine (Taipei)       Date:  2014-08-06

Review 7.  Translating IL-6 biology into effective treatments.

Authors:  Ernest H Choy; Fabrizio De Benedetti; Tsutomu Takeuchi; Misato Hashizume; Markus R John; Tadamitsu Kishimoto
Journal:  Nat Rev Rheumatol       Date:  2020-04-23       Impact factor: 20.543

Review 8.  Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus.

Authors:  Przemysław Kotyla; Olga Gumkowska-Sroka; Bartosz Wnuk; Kacper Kotyla
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-28

9.  Serum levels of interleukin-6 are not dependent on the kidney function.

Authors:  L Nässberger
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

10.  Dimeric and polymeric IgA, but not monomeric IgA, enhance the production of IL-6 by human renal mesangial cells.

Authors:  T J Reterink; W E Schroeijers; L A Es; M R Daha
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.